3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
7
Rectal Neoplasms
5
Nasopharyngeal Carcinoma
5
Colorectal Neoplasms
5
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Pancreatic Neoplasms
3
Melanoma
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Advanced Solid Tumor
2
Triple Negative Breast Neoplasms
1
Squamous Cell Non-small Cell Lung Cancer
1
Solid Tumor, Adult
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms by Site
1
Interventions
Oxaliplatin
10
pembrolizumab
8
Fluorouracil
8
Leucovorin
7
Paclitaxel
5
Gemcitabine
5
Docetaxel
5
Capecitabine
5
Cyclophosphamide
4
Blood Specimen Collection
4
zolbetuximab
3
fludarabine
3
darolutamide
3
cemiplimab
3
Trastuzumab
3
Taxes
3
Ramucirumab
3
Radiotherapy
3
Radiosurgery
3
Irinotecan
3
trastuzumab deruxtecan
2
enzalutamide
2
durvalumab
2
Standard of Care
2
Nivolumab
2
Folfox protocol
2
Dexamethasone
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
tucatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Adenocarcinoma
×
spartalizumab
×
Clear all
NCT06121700
2023-11-08
Miracle-G
Fudan University
Phase 2
Recruiting
55 enrolled